Chimeric Therapeutics (ASX:CHM) Other Long-Term Liabilities : A$2.63 Mil (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Chimeric Therapeutics Other Long-Term Liabilities?

Chimeric Therapeutics's other long-term liabilities for the quarter that ended in Dec. 2023 was A$2.63 Mil.

Chimeric Therapeutics's quarterly other long-term liabilities increased from Dec. 2022 (A$0.16 Mil) to Jun. 2023 (A$2.02 Mil) and increased from Jun. 2023 (A$2.02 Mil) to Dec. 2023 (A$2.63 Mil).

Chimeric Therapeutics's annual other long-term liabilities declined from Jun. 2021 (A$4.02 Mil) to Jun. 2022 (A$0.15 Mil) but then increased from Jun. 2022 (A$0.15 Mil) to Jun. 2023 (A$2.02 Mil).

Chimeric Therapeutics Other Long-Term Liabilities Historical Data

The historical data trend for Chimeric Therapeutics's Other Long-Term Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Chimeric Therapeutics Other Long-Term Liabilities Chart

Chimeric Therapeutics Annual Data

Trend

Jun21

Jun22

Jun23

Other Long-Term Liabilities

Chimeric Therapeutics Semi-Annual Data
	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Other Long-Term Liabilities	Get a 7-Day Free Trial			-	-	-	-	-

Chimeric Therapeutics Other Long-Term Liabilities Calculation

Other Long-Term Liabilities are the other liabilities on the balance sheet that do not need to be repaid within the next 12 months, but still need to be repaid over time. For instance, on Wal-Mart's balance sheet, there are items called Long Term obligations under capital leases, deferred income taxes, and redeemable non-controlling interest. These are all Other Long-Term Liabilities.

Chimeric Therapeutics Other Long-Term Liabilities Related Terms

Thank you for viewing the detailed overview of Chimeric Therapeutics's Other Long-Term Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Chimeric Therapeutics (ASX:CHM) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Chimeric Therapeutics Ltd (ASX:CHM) » Definitions » Other Long-Term Liabilities

Comparable Companies

Traded in Other Exchanges

CHMMF:USA

Address

62 Lygon Street, Level 3, Carlton South, Melbourne, VIC, AUS, 3053

Website

https://www.chimerictherapeutics.com

Chimeric Therapeutics Ltd is a biotechnology company engaged in developing a cancer cell therapy drug. Its technology CLTX-CAR T uses chlorotoxin, a peptide discovered in scorpion venom, as the tumor-targeting component of the CAR to reprogram T cells. Primary products under development by the company are NK Cell Derived Allogenic Therapies and T Cell Derived Autologous Therapies. The company has one segment being the research, development and commercialization of health technologies.

Chimeric Therapeutics (ASX:CHM) Headlines

No Headlines